We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Enanta Pharmaceuticals Inc (ENTA) USD0.01

Sell:$58.59 Buy:$58.73 Change: $0.18 (0.31%)
Market closed |  Prices as at close on 25 January 2022 | Switch to live prices |
Change: $0.18 (0.31%)
Market closed |  Prices as at close on 25 January 2022 | Switch to live prices |
Change: $0.18 (0.31%)
Market closed |  Prices as at close on 25 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Enanta Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in development of small molecule drugs for the treatment of viral infections and liver diseases. The Company has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). The Company has discovered glecaprevir, a protease inhibitor discovered and developed for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET. Its product candidates also include EDP-514, EDP-305 and EDP-938. The Company's subsidiary is Enanta Pharmaceuticals Security Corporation.

Contact details

500 Arsenal St
United States
+1 (617) 6070800

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.16 billion
Shares in issue:
20.32 million
United States
US dollar

Key personnel

  • Jay Luly
    President, Chief Executive Officer, Director
  • Paul Mellett
    Chief Financial Officer, Senior Vice President - Finance and Administration
  • Yat Sun Or
    Senior Vice President - Research and Development, Chief Scientific Officer
  • Nathaniel Gardiner
    Senior Vice President, General Counsel
  • Nathalie Adda
    Senior Vice President and Chief Medical Officer
  • Tara Kieffer
    Senior Vice President - New Product Strategy and Development
  • Brendan Luu
    Senior Vice President - Business Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.